Pub. Date : 2013 Jun
PMID : 23733083
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). | Erlotinib Hydrochloride | ALK receptor tyrosine kinase | Homo sapiens |